Sibeprenlimab

Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL) . Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR) . Sibeprenlimab is promising for the research of IgA nephropathy (IgAN) [1][2][3].

Product Specifications

CAS Number

[2382896-07-1]

Product Name Alternative

VIS649

UNSPSC

12352203

Target

SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sibeprenlimab.html

Purity

99.82

Solubility

10 mM in DMSO

Smiles

[Sibeprenlimab]

Molecular Weight

(146.36 kDa)

References & Citations

[1]Mohit Mathur, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022 Feb 8;7 (5) :993-1003. |[2]Mathur M, et al. A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. J Clin Med. 2023 Nov 4;12 (21) :6927. |[3]Refardt J, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023 Nov 16;389 (20) :1877-1887.|[4]Myette JR, et al. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019 Jul;96 (1) :104-116.